Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Debbie Shawcross

Has grant

Professor of Hepatology and Chronic Liver Failure

King’s College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Biochemistry Biochemistry professors in United Kingdom

About

Debbie Shawcross is a Reader in Hepatology and Honorary Consultant in Hepatology at King's College London, UK. Her research focuses on cirrhosis, antimicrobial resistance in liver disease, and the application of artificial intelligence in hepatology. Recent publications include investigations into faecal microbiota transplant, organ failures in cirrhosis patients, and the serological response to SARS-CoV-2 vaccinations in pediatric transplant recipients.

Recent Grants

Grant: Open

Faecal Transplantation for Alcohol-Related Hepatitis

Open Date: 2026-04-01

Close Date: 2029-06-30

Grant: Open

Apixaban to Prevent dEcompensation of eArly liver CirrHosis (APEACH)

Open Date: 2025-06-01

Close Date: 2030-11-30

Grant: Open

Defining the inflammatory pathophysiology of depression in cirrhosis using an in vitro model of human hippocampal neurogenesis

Open Date: 2025-04-30

Close Date: 2027-04-29

Grant: Close

An Alcohol-Related liver disease Multi-Stakeholder Hub (ARMS-Hub) to enhance research activity in underserved communities in the UK

Open Date: 2023-03-01

Close Date: 2024-02-29

Grant: Close

A PROspective double-blind placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve outcomEs in patients with cirrhosis - PROMISE trial.

Open Date: 2021-05-01

Close Date: 2026-04-30

Articles (45)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (37)

Rajiv Jalan

Professor of Hepatology

University College London

UNITED KINGDOM

Debbie Shawcross

Research Interests

Explore related searches

About

Recent Grants

Articles (45)

Making space and opportunities for talent to grow

Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN

Hepatic encephalopathy: Part 4, driving in the UK

Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma

Integrative host–microbiome modeling uncovers the implication of oral–gut translocation in advanced cirrhosis

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice

Response to the Comment on "Burden and global distribution of antimicrobial resistance in non-bloodstream infections among adults with cirrhosis

The Global ACLF Consensus

From ambition to delivery: why realistic research matters in UK gastroenterology and hepatology

Hepatic encephalopathy in chronic liver disease

Burden and Global Distribution of Antimicrobial Resistance in Non-Bloodstream Infections Among Adults with Cirrhosis

Changes in alcohol use following a diagnosis of alcohol-related liver disease: A clinical cohort study

Ethnicity, diversity, and inclusion in gastroenterology

A global consensus on the critical care management of acute-on-chronic liver failure patients

Diverging trends and persistent inequities in cirrhosis burden across sub-Saharan Africa: projections to 2040

From evidence to action: The WHO–Imperial–EASL Collaborating Centre on Steatotic Liver Disease

EASL 2026 Interview: Debbie Shawcross

From science to public health impact: Enacting the recommendations of the EASL-Lancet Commission on liver health in Europe

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients with Severe Alcohol-associated Hepatitis

Recent advances in our understanding of the gut microbiome

The barriers for uptake of artificial intelligence in hepatology and how to overcome them

Bacterial diversity, viability and stability in lyophilised faecal microbiota capsules support ongoing clinical use

FMT for hepatic encephalopathy? The THEMATIC trial aims to make it a ‘no brainer’

Defining Organ Failures in Patients with Cirrhosis

Erratum to "Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO)

Global Trends in Antimicrobial Resistance Among Cirrhosis Patients with Bacteremia

Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO)

Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease

Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults

Adolescent sobriety under siege – an urgent call to protect children from alcohol harms

Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers

Advocating for the implementation of the new nomenclature for steatotic liver disease: A call to action for the national associations

Infection, inflammation and hepatic encephalopathy from a clinical perspective

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease

Ammonia – an enduring foe – What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy

The microbiome in portal hypertension

Modulation of the Gut Microbiota to Control Antimicrobial Resistance (AMR)—A Narrative Review with a Focus on Faecal Microbiota Transplantation (FMT)

Reply to: “Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?”

Reply to: “Ammonia - an old friend with a new area of application”

The clinical relevance of acute‐on‐chronic liver failure in medical procedures: Endoscopy, interventions and surgery

The rise and fall and rise again of ammonia as a therapeutic target in HE

Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver Transplantation

Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis

Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma?

Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation?

Collaborators (37)

Rajiv Jalan

Piero Amodio

Octavi Bassegoda

Abdel Douiri

Nicola Kalk

Aleksander Krag

Paul Royall

Tom Luedde

Simon D. Goldenberg

Maja Thiele

Neil Rajoriya

James L Alexander

Vincent Wong

Minneke J. Coenraad

Peter Jepsen

James Mason

William Bernal

Richard Moreau

Josepmaria Argemi

Shilpa Chokshi

Francesco Paolo Russo

Manu Shankar-Hari

Tobias Seraphin

Karen Louise Thomsen

sven Francque

Ruben Hernaez

Srinivasan Dasarathy

Christopher Rose